Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00

Zura Bio (NASDAQ:ZURA) had its price target increased by Chardan Capital from $10.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on the company. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Wedbush assumed coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Oppenheimer dropped their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Stock Up 4.5%

Shares of NASDAQ ZURA opened at $5.62 on Monday. The firm has a 50-day simple moving average of $6.18 and a 200-day simple moving average of $4.62. The stock has a market capitalization of $365.41 million, a price-to-earnings ratio of -5.30 and a beta of 0.18. Zura Bio has a 52 week low of $0.97 and a 52 week high of $7.44.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.31). As a group, equities research analysts expect that Zura Bio will post -0.65 EPS for the current year.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. This represents a 43.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 14.23% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new stake in Zura Bio in the fourth quarter valued at $30,000. Squarepoint Ops LLC grew its holdings in shares of Zura Bio by 34.6% during the 4th quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after purchasing an additional 8,680 shares during the period. Bank of America Corp DE increased its position in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the last quarter. Scientech Research LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $45,000. Finally, State Street Corp raised its holdings in Zura Bio by 8.3% in the 4th quarter. State Street Corp now owns 156,363 shares of the company’s stock valued at $819,000 after buying an additional 12,000 shares during the period. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.